Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
53 studies found for:    urology AND mayo clinic | Open Studies | null

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-102
2 Recruiting Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Condition: Kidney Stones
Interventions: Device: Cyberwand;   Device: Stonebreaker;   Device: Lithoclast Select
3 Recruiting Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
Condition: Stress Urinary Incontinence
Interventions: Biological: Roll-in;   Other: Placebo;   Biological: AMDC for USR
4 Recruiting Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
5 Recruiting Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
6 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Intervention: Drug: Pazopanib Hydrochloride
7 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
8 Recruiting Renal Mass Registry
Condition: Renal Cell Carcinoma
Intervention: Other: questionnaire
9 Recruiting Dent Disease Mutation Genotyping
Condition: Dent Disease
Intervention: Genetic: Genetic Analysis
10 Recruiting Rare Kidney Stone Consortium Patient Registry
Conditions: Primary Hyperoxaluria;   Dent Disease;   Cystinuria;   APRT Deficiency
Intervention:
11 Recruiting Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer;   Liver Cancer
Interventions: Drug: hypoxia-activated prodrug TH-302;   Drug: sorafenib tosylate;   Genetic: protein analysis;   Other: laboratory biomarker analysis
12 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
13 Recruiting Review of Kidney Biopsies of Dent Disease Patients
Condition: Dent Disease
Intervention: Procedure: Renal Biopsy
14 Recruiting MEmbranous Nephropathy Trial Of Rituximab
Condition: Idiopathic Membranous Nephropathy
Interventions: Drug: Rituximab;   Drug: Cyclosporine
15 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
16 Recruiting Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy;   Drug: docetaxel
17 Recruiting Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Condition: Dent Disease
Intervention: Drug: Phosphorus Supplement
18 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Pharmacological Study
19 Recruiting Primary Hyperoxaluria Mutation Genotyping/Phenotyping
Condition: Primary Hyperoxaluria
Intervention: Other: Genetic Analysis
20 Recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years